GlassScriptPhysician profile
Emily Spann
NPI 1871080028
$1,448.76
in general payments reported to CMS, 2019-2025
22 companies · $449 in 2025
The $449 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $430 · 2024: $370 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243 · Travel and Lodging: $6.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.03 |
| Travel and Lodging | $6.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $192.64 | 2022-2024 | Veozah, Myrbetriq |
| Intuitive Surgical, INC. | $151.29 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $125.87 | 2022-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $121.31 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $112.71 | 2023-2025 | Myfembree, Gemtesa |
| Optumhealth Care Solutions, LLC | $94.37 | 2023-2025 | Vivify Health Care Team Portal, Zyno Solutions, Eitan Medical |
| Sage Therapeutics, LLC | $85.39 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $84.82 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $79.85 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.88 | 2022-2023 | |
| Exeltis, USA INC. | $48.62 | 2022-2025 | Slynd |
| Millicent US INC | $47.89 | 2025 | Intrarosa, Femlyv, Femring |
| Therapeuticsmd, INC. | $39.29 | 2022 | |
| Merck Sharp & Dohme LLC | $35.75 | 2023-2025 | Gardasil 9 |
| Shield Therapeutics INC | $32.21 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.34 | 2024 | Injectafer |
| Minerva Surgical, INC | $23.09 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $22.63 | 2023 | Exparel |
| Pfizer INC. | $18.07 | 2023 | |
| Innovation Technologies INC | $16.76 | 2025 | Irrisept |
| Smith+Nephew, INC. | $15.60 | 2025 | Pico |
| Aspira Women'S Health INC | $14.38 | 2023 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Spann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.